Microsurgery robot market set to reach $2 billion by 2026

2026年显微手术机器人市场规模将达20亿

2021-01-22 12:38:26 Roboticstrends

本文共989个字,阅读需3分钟

The microsurgery robot market is projected to attain “remarkable revenue growth” in view of rapid technological advancements in the field of medical science, according to a recent study by market research firm Global Market Insights. The analyst forecasts that the microsurgery robot market will reach $2 billion by 2026. Growing inclination towards creating innovative microsurgery devices that are capable of undertaking complex surgeries could massively enhance the product demand in the future. Surging demand for minimally invasive surgeries owing to its notable benefits like quick recovery time could positively impact business outlook. Increasing number of research projects being conducted worldwide are expected to raise the demand for microsurgery robots. The research institutes segment recorded over 14.4 percent compound annual growth rate in the analysis timeframe. The need to enhance accuracy of surgery and decrease the cost of surgical robots is likely to increase the number of R&D activities. Support by government organizations and funding in research activities is some other segment growth drivers. Microsurgery robots are widely used in oncological, cardiovascular, and neurological surgeries. Advanced surgical robots find application in hospitals and ambulatory surgery centers, which is expected to raise the number of robotic-assisted surgical procedures. Considering rising application, microsurgery robot manufacturers are working on novel, advanced technologies and products. Endorsing a huge application base, the global microsurgery robot market is expected to generate massive remuneration from the oncology surgery segment in the upcoming years. In fact, it was reported that the sector acquired a fair share of 20 percent in 2019 and is looking forward to garnering significant gains, mainly due to the product’s massive use in cancer treatment. That said, it would be safe to declare that rising cases of cancer would offer a positive boost to the demand for microsurgery robots. It has been observed that Asia Pacific holds a huge patient pool when it comes to the prevalence of chronic ailments and diseases. In this case, it would be overt to state that the region would emerge as a strong growth ground for overall microsurgery robot market over the span of six years. This growth predominantly comes from the surging demand for microsurgery robots and the advantages offered by these including reduced risks of infection, less pain, reduction in hospital stays, and others. Apparently, this elevating demand has propelled several market players to step up and undertake initiatives to make such robots available in the region. For example, Corindus Vascular Robotics had in mid-2018 announced receiving approval from PMDA for the commercialization of Corpath GRX system in Japan. As mentioned, companies operating in the microsurgery robot market space are leaving no stone unturned to provide ample benefits of these products to their huge consumer base. Companies like Auris Health, Intuitive Surgical, Zimmer Biomet, and Medtronic amongst others engaging in diverse industry tactics to strengthen their product portfolio to gain a competitive edge in the overall business space.
根据市场研究公司Global market Insights最近的一项研究,鉴于医疗科学领域的快速技术进步,显微手术机器人市场预计将获得显著的收入增长。 该分析师预测,到2026年,显微手术机器人市场规模将达到20亿。 越来越多的人倾向于创造能够进行复杂手术的创新显微外科设备,这将极大地提高未来的产品需求。 对微创手术的需求激增,因为其显著的好处,如恢复时间快,可能会对商业前景产生积极影响。 越来越多的研究项目正在世界各地进行,预计将提高对显微手术机器人的需求。 研究机构分部在分析期间录得超过14.4%的复合年增长率。提高手术精度和降低手术机器人成本的需求可能会增加研发活动的数量。政府组织的支持和对研究活动的资助是部分增长的另一些驱动因素。 显微手术机器人广泛应用于肿瘤,心血管和神经外科。先进的手术机器人在医院和非卧床手术中心得到应用,这有望提高机器人辅助手术程序的数量。 考虑到日益增长的应用,显微手术机器人制造商正致力于开发新颖,先进的技术和产品。 全球显微手术机器人市场拥有庞大的应用基础,有望在未来几年从肿瘤外科领域获得巨大的收入。 事实上,据报道,该行业在2019年获得了20%的公平份额,并期待着获得显著收益,主要是由于该产品在癌症治疗中的大量使用。 话虽如此,可以肯定地说,癌症病例的增加将会对显微手术机器人的需求起到积极的推动作用。 据观察,就慢性病的流行而言,亚太地区拥有庞大的患者群。 在这种情况下,这将是公开的声明,该地区将出现作为一个强有力的增长的整体显微手术机器人市场在六年的跨度。 这一增长主要来自于对显微手术机器人的需求激增,以及这些机器人提供的优势,包括降低感染风险,减轻痛苦,减少住院时间等。 显然,这一不断增长的需求推动了几个市场参与者加快步伐,采取主动行动,在该地区提供这类机器人。例如,Corindus Vascular Robotics在2018年年中宣布获得PMDA批准,将Corpath GRX系统在日本商业化。 如前所述,在显微外科手术机器人市场空间运营的公司正千方百计地为其庞大的消费者基础提供这些产品的充足利益。 Auris Health,Intuitive Surgical,Zimmer Biomet和Medtronic等公司采用不同的行业策略来加强其产品组合,从而在整个商业空间中获得竞争优势。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文